Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
3.450
+0.120 (3.60%)
Dec 22, 2025, 4:00 PM EST - Market closed
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,292,513
Market Cap
7.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 1 | 33.33% |
| Dec 31, 2021 | 3 | 0 | - |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACXP News
- 4 weeks ago - Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals - PRNewsWire
- 5 weeks ago - Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update - PRNewsWire
- 6 weeks ago - Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens - PRNewsWire
- 7 weeks ago - Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference - PRNewsWire
- 2 months ago - Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update - PRNewsWire
- 2 months ago - Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - PRNewsWire
- 2 months ago - Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection - PRNewsWire